SCHEMBL546440

SCHEMBL546440

COC(=O)c1ccc2ccc(Oc3ccnc(C(=O)OC(C)(C)C)c3)cc2c1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.41
HTT P42858 1/20 0.41
BRAF P15056 9/20 0.41
KDR P35968 5/20 0.41
CYP19A1 P11511 1/20 0.40
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
KDM4E B2RXH2 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
CYP17A1 P05093 1/20 0.40
CYP3A4 P08684 1/20 0.40
P2RX3 P56373 1/20 0.39
RAF1 P04049 3/20 0.39
FPR2 P25090 1/20 0.39
SCN9A Q15858 1/20 0.39
EPHX2 P34913 1/20 0.39
HGFAC Q04756 1/20 0.39
PTPN11 Q06124 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL545151 0.90 KDM4E (0.45) BRAFKDRKDM4EPOLBMAPT
SCHEMBL545540 0.86 KDM4E (0.47) ALOX15HTTBRAFKDRCYP19A1
Hydrochloric Acid SCHEMBL546682 0.85 KDM4E (0.46) ALOX15HTTBRAFKDRCYP19A1
SCHEMBL19478119 0.84 BRAF (0.58) BRAFKDRRAF1EPHX2
SCHEMBL546233 0.84 P2RX3 (0.45) ALOX15HTTBRAFKDRCYP19A1
SCHEMBL4739757 0.83 ALOX15 (0.39) ALOX15HTTKDRCYP19A1CYP11B1
SCHEMBL4202008 0.77 RAF1 (0.44) BRAFKDRMAPTRAF1FPR2
SCHEMBL2503456 0.76 KDR (0.43) BRAFKDRRAF1
SCHEMBL12329785 0.76 NR4A1 (0.45) BRAFKDRRAF1EPHX2
SCHEMBL12852960 0.75 RAF1 (0.54) BRAFKDRCYP17A1RAF1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110687-B2 Bicyclic compounds with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-02-07 US disclosed
US-8110687-B2 Bicyclic compounds with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-02-07 US disclosed
US-8110687-B2 Bicyclic compounds with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-02-07 US disclosed
US-20070149533-A1 Bicyclic compounds with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-06-28 US disclosed
US-20070149533-A1 Bicyclic compounds with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-06-28 US disclosed
US-20070149533-A1 Bicyclic compounds with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-06-28 US disclosed
WO-2007067444-A1 BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149533-A1 Bicyclic compounds with kinase inhibitory activity MAP3K20, MAP3K1, MAP3K5 ALOX15 4099/4885HTT 3268/4885BRAF 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.